Merck’s V920 Ebola Zaire Vaccine Receives CHMP Positive Opinion to Protect Against Ebola Virus Disease

Shots:

• The EMA’s CHMP has adopted the positive opinion recommending conditional marketing authorization for the V920 Ebola Zaire vaccine (rVSVΔG-ZEBOV-GP, live), indicated for active immunization of individuals ≥18yrs. to protect against EVD caused by Zaire Ebola virus
• If EC affirmed CHMP opinion, it will grant centralized marketing authorization with unified labeling to the V920 Ebola Zaire Vaccine and will be authorized under the name Ervebo
• V920 is a recombinant, replication-competent Ebola vaccine, consisting of a vesicular stomatitis virus to provoke a neutralizing immune response to the Ebola virus. The US FDA has accepted its BLA in Sept’2019 and granted it PR with a PDUFA date as Mar 14, 2020

Click here to­ read full press release/ article | Ref: Merck | Image: Barron